Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati
{"title":"A Review on Tau Targeting Biomimetics Nano Formulations: Novel\nApproach for Targeting Alzheimer's Diseases","authors":"Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati","doi":"10.2174/0118715249289120240321065936","DOIUrl":null,"url":null,"abstract":"\n\nCentral nervous system disorders are prevalent, profoundly debilitating, and poorly\nmanaged. Developing innovative treatments for these conditions, including Alzheimer's disease,\ncould significantly improve patients' quality of life and reduce the future economic burden on\nhealthcare systems. However, groundbreaking drugs for central nervous system disorders have\nbeen scarce in recent years, highlighting the pressing need for advancements in this field. One significant\nchallenge in the realm of nanotherapeutics is ensuring the precise delivery of drugs to their\nintended targets due to the complex nature of Alzheimer's disease. Although numerous therapeutic\napproaches for Alzheimer's have been explored, most drug candidates targeting amyloid-β have\nfailed in clinical trials. Recent research has revealed that tau pathology can occur independently of\namyloid-β and is closely correlated with the clinical progression of Alzheimer's symptoms. This\ndiscovery suggests that tau could be a promising therapeutic target. One viable approach to managing\ncentral nervous system disorders is the administration of nanoparticles to neurons, intending to\ninhibit tau aggregation by directly targeting p-tau. In Alzheimer's disease, beta-amyloid plaques\nand neurofibrillary tau tangles hinder neuron transmission and function. The disease also triggers\npersistent inflammation, compromises the blood-brain barrier, leads to brain shrinkage, and causes\nneuronal loss. While current medications primarily manage symptoms and slow cognitive decline,\nthere is no cure for Alzheimer's.\n","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":" 78","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715249289120240321065936","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Psychology","Score":null,"Total":0}
引用次数: 0
Abstract
Central nervous system disorders are prevalent, profoundly debilitating, and poorly
managed. Developing innovative treatments for these conditions, including Alzheimer's disease,
could significantly improve patients' quality of life and reduce the future economic burden on
healthcare systems. However, groundbreaking drugs for central nervous system disorders have
been scarce in recent years, highlighting the pressing need for advancements in this field. One significant
challenge in the realm of nanotherapeutics is ensuring the precise delivery of drugs to their
intended targets due to the complex nature of Alzheimer's disease. Although numerous therapeutic
approaches for Alzheimer's have been explored, most drug candidates targeting amyloid-β have
failed in clinical trials. Recent research has revealed that tau pathology can occur independently of
amyloid-β and is closely correlated with the clinical progression of Alzheimer's symptoms. This
discovery suggests that tau could be a promising therapeutic target. One viable approach to managing
central nervous system disorders is the administration of nanoparticles to neurons, intending to
inhibit tau aggregation by directly targeting p-tau. In Alzheimer's disease, beta-amyloid plaques
and neurofibrillary tau tangles hinder neuron transmission and function. The disease also triggers
persistent inflammation, compromises the blood-brain barrier, leads to brain shrinkage, and causes
neuronal loss. While current medications primarily manage symptoms and slow cognitive decline,
there is no cure for Alzheimer's.
期刊介绍:
Central Nervous System Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new central nervous system agents. Containing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Central Nervous System Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.